ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Melanoma
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Charlotte, North Carolina, United States and 83 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Charlotte, North Carolina, United States and 123 other locations

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying E...

Enrolling
Non-Small Cell Lung Cancer
EGFR/HER2 Exon 20 Insertion Mutation
Drug: STX-721/PFL-721 (Escalated)
Drug: STX-721/PFL-721 (RP2D)

Phase 1, Phase 2

Pierre Fabre
Pierre Fabre

Charlotte, North Carolina, United States and 22 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. ...

Enrolling
Lung Cancer, Non-squamous, Non-small Cell
Drug: carboplatin
Drug: zongertinib

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Rock Hill, South Carolina, United States and 161 other locations

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

(SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Biological: Sacituzumab Govitecan-hziy (SG)
Drug: Docetaxel

Phase 3

Gilead Sciences
Gilead Sciences

Charlotte, North Carolina, United States and 226 other locations

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and...

Active, not recruiting
Non Small Cell Lung Cancer
Lung Cancer Stage III
Drug: Paclitaxel
Drug: Durvalumab

Phase 2

Wake Forest University (WFU)
Wake Forest University (WFU)

Charlotte, North Carolina, United States

Locations recently updated

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The pr...

Enrolling
Non-small Cell Lung Cancer
Other: Placebo
Biological: Intismeran autogene

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 220 other locations

Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)

as maintenance therapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC) wh...

Active, not recruiting
Lung Cancer, Non-Small Cell
Biological: Pembrolizumab
Drug: Niraparib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Charlotte, North Carolina, United States and 188 other locations

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788

Phase 1, Phase 2

Takeda
Takeda

Charlotte, North Carolina, United States and 61 other locations

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prelimi...

Enrolling
Non Small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Drug: Pemetrexed
Drug: Carboplatin + Pemetrexed

Phase 1, Phase 2

Phanes Therapeutics

Huntersville, North Carolina, United States of America and 5 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems